Summary In this review we shall discuss the biological rationale and the clinical findings obtained using Interleukin 2 (IL2)-based immunotherapy in the management of cancer patients. Objective and long-lived clinical responses have been documented in a proportion of cases, particularly renal cell carcinoma, melanoma and acute myeloid leukaemia. Though encouraging, the clinical use of IL2 has so far been limited by toxicity, as well as by the heterogeneous and unpredictable responses and by the lack of specific anti-tumour effect. These considerations have led to the belief that more sophisticated technologies aimed at introducing the IL2 gene into the neoplastic cells may potentially overcome some of the limitations coupled to the in vivo infusion of high doses of IL2. The data accumulated in animal models and, more recently, also with human tumour cells indicate that the IL2 gene may be successfully inserted into neoplastic cells. The constitutive secretion of IL2 by the tumour cells leads to a reduced or abrogated tumorigenicity in several different tumour models. The evidence that in some experimental tumours the transduction of the IL2 gene into the neoplastic cells may elicit a specific cytotoxic response and confer anti-tumour memory, suggests that vaccination protocols based on this innovative strategy may represent a potential new tool in the management of cancer patients.
These last few years have witnessed a new wave of excitement in the advocates that biological treatment, if adequately planned, may have a role in the management of patients with cancer. In addition to the documented efficacy of alpha Interferon (IFN) in different neoplastic conditions (Goldstein & Laszlo, 1986) , particularly hairy cell leukaemia and chronic myeloid leukaemia, this has largely been contributed by the use in clinical practice of Interleukin 2 (IL2)-based immunotherapeutic protocols. This innovative therapeutic modality stems from the recognition that IL2-first described in the mid seventies as T-cell growth factor (TCGF) because of its proliferative effect on normal T-lymphocytes (Morgan et al., 1976) -is a cytokine with a highly pleiotropic activity (for a review see Smith, 1988) . In the context of potential control of tumour growth, IL2 is capable of boosting the natural killer (NK) compartment, augmenting the cytotoxicity of human monocytes, inducing T-helper function and increasing the reactivity of previously generated cytotoxic T-lymphocytes (CTL) (Ortaldo et al., 1984; Erard et al., 1985; Forni et al., 1988) . Most relevantly, in the early eighties it was shown that following incubation with IL2, normal peripheral blood lymphocytes revealed a previously unrecognised cytotoxic activity mediated by the so-called LAK (lymphokine activated killer) effectors (Grimm et al., 1982) . Characteristically, these non-MHC (major histocompatibility complex)-restricted effectors are capable of lysing NKresistant tumour cells, whilst showing a lower degree of toxicity towards normal cells. The studies carried out in experimental models have convincingly shown that the infusion of IL2, either alone or in combination with ex-vivo generated LAK cells, is capable of displaying an antineoplastic effect which can abrogate or delay the growth of established pulmonary and liver metastases in different tumour models (Mule' et al., 1984; Lafraniere & Rosenberg, 1985) . More effective responses have been recorded by combining IL2 with tumour infiltrating lymphocytes (TIL) rather than with LAK cells (Rosenberg et al., 1986; , suggesting that lymphocytes with selective killing capacity may infiltrate the tumour site possibly through a mechanism of specific tumour associated antigen (TAA) recognition. These effector cells appear to be MHC-restricted and their action can be blocked by monoclonal antibodies against MHC class I antigens.
These pre-clinical observations opened the way to the numerous clinical studies which have assessed first the feasibility of employing IL2, with or without LAK/TIL cells, in the management of patients with cancer, and thereafter the potential anti-neoplastic efficacy of this novel therapeutic strategy.
IL2 in the management of cancer patients
The clinical studies carried out have demonstrated for the first time that in a proportion of cancer patients with advanced disease and resistant to conventional treatment, a pure immunological approach based on the administration of high doses of IL2, with or without ex-vivo generated LAK or TIL cells, could induce clinically documentable regressions 1988; West et al., 1987; Parkinson et al., 1990) . Based on the earlier clinical findings and on an extensive review of 652 patients treated (Rosenberg et al., 1989) , the most favourable results have been consistently documented in metastatic renal cell cancer and melanoma, in which complete or, more frequently, partial responses in the order of about 20% are to be expected. Some of these responses may be long-lived. Of 18 complete responders reported by Rosenberg et al. (1989) , ten were in persistent complete remission between 18 and 52 months from treatment. A higher therapeutic efficacy has been recently suggested in renal cell carcinoma patients 'induced' with IL2 plus LAK cells and 'maintained' with a more prolonged period of low-dose daily IL2 administration (Thompson et al., 1992) . Overall better responses have been reported in advanced melanoma using IL2 and TIL ; interestingly, objective responses could be documented also in patients who were resistant to IL2 alone. These results appear conceivable in light of the evidence that specific cytotoxic T-lymphocytes (CTL) directed against the autologous tumour cell population have been documented in human metastatic melanoma (De Vries & Spits, 1984; Anichini et al., 1985) . In addition, melanoma is the tumour in which CTLs have been used to define and clone the first TAA in human cancer (Van Der Bruggen et al., 1991 (Dawson et al., 1986; Oshimi et al., 1986; Lotzova et al., 1987; Fierro et al., 1988; Adler et al., 1988; Lista et al., 1989; Foa et al., 1990a) . Furthermore, data accumulated from in vitro and in vivo nude mice experiments indicate the unlikelihood that leukaemic blasts may proliferate to a significant degree in the presence of IL2 (Foa et al., 1990a) . The clinical studies started more than 4 years ago have documented the feasibility of administering recombinant IL2 to patients with acute leukaemia, both in terms of doses which may be infused and of overall toxicity (Foa et al., 1989 (Foa et al., , 1990b (Foa et al., , 1991a Maraninchi et al., 1991; Lim et al., 1992) . Furthermore, they have suggested that IL2 may display an anti-leukaemic effect, particularly in acute myeloid leukaemia patients with a limited proportion of detectable resistant blasts (Foa et al., 1990b (Foa et al., , 1991a Lim et al., 1992) . In this clinical situation complete and prolonged remissions have been obtained with repeated cycles of IL2 alone (Foa et al., 1990b (Foa et al., , 1991a Lim et al., 1992) .
Pilot studies have also shown the feasibility of administering IL2 to acute leukaemia patients who have undergone an autologous bone marrow transplant (Blaise et al., 1990; Higuchi et al., 1991; Soiffer et al., 1992; Meloni et al., 1992) . These findings suggest the potential use of IL2 after engraftment to boost the immune system of the host in an attempt to control or reduce/eradicate minimal residual disease following maximum cytoreductive treatment. This approach gains further strength by the possibility that endogenous and IL2-responsive LAK precursor cells may be detected in the circulation early after an autotransplant (Reittie et al., 1989; Higuchi et al., 1989) . In view of the progressively growing use of bone marrow and peripheral blood stem cell autografting procedures in solid tumours, it is foreseeable that the application of this immunotherapeutic approach in the management of cancer patients will expand in the next few years.
The likelihood that the anti-neoplastic effect observed in solid tumours and in acute leukaemia patients may be mediated by the immune system of the host activated by the IL2 administered, is documented by the multiple morphological, phenotypic and functional modifications observed in the treated patients. On haematological grounds, each cycle of IL2 is followed by a more or less evident absolute lymphocytes, characterised in particular by a marked increase in large granular lymphocytes, which physiologically comprise cytotoxic effectors. The immunological changes may be summarised by the expression of activation markers, as well as by the amplification of the NK and LAK functions and by the in vivo release of two cytokines-IFN gamma and Tumour Necrosis Factor (TNFa)-with known anti-proliferative activity Hank et al., 1988; Gottlieb et al., 1989; Heslop et al., 1989; Foa et al., 1991b) . (West et al., 1987) , continuous infusion protocols using a daily dose escalating scheme (Foa et al., 1990b; 1991a) , prolonged low-dose daily infusion (Caligiuri et al., 1991) , as well as loco-regional injections of IL2 directly in the tumour area or around tumour-draining lymphnodes (Cortesina et al., 1988 More relevantly, the constitutive release of IL4 (Tepper et al., 1989; Golumbek et al., 1991) , IL6 (Porgador et al., 1992) , IL7 (Hock et al., 1991) , IFN gamma (Watanabe et al., 1989; Gansbacher et al., 1990a) , TNF alpha (Blankenstein et al., 1991; Asher et al., 1991) and G-CSF (Colombo et al., 1991) by the genetically engineered tumour cells has resulted in a decreased or abrogated tumorigenicity. The mechanisms by which this anti-tumour response, induced by the release of the different cytokines and growth factors, is obtained is most likely heterogeneous, including in some models local intra-tumoural inflammation and in others the generation of cytotoxic T-lymphocytes. The analysis of the complex and only partly understood mechanisms underlying this remarkable anti-tumour effect elicited by the 'manipulation' of the immune system of the host following transduction of cytokine/growth factor genes other than IL2 goes beyond the scopes of this review.
IL2-gene transfer into tumour cells
Conceptually, the productive insertion of the IL2 gene into tumour cells should help to circumvent two of the key limitations associated with the in vivo administration of IL2, i.e. (1) the relevant side effects experienced in all patients with the high doses of IL2 required to elicit an anti-tumour effect, and (2) the lacking demonstration that the infusion of IL2 can induce the generation of a specific killing machinery. The expected goal is that the in vivo infusion of tumour cells transduced with the IL2 gene will allow the constitutive release of amounts of IL2 too low to produce significant side effects to the patient, but sufficient to generate an antitumour response via the immune system of the host. This should become apparent through the amplification of the NK compartment, the generation of LAK effectors and the local release of TNF alpha and IFN gamma. In addition, the SYSTEMC -CmcU.nN presence or putative presence of TAA on tumour cells -at the site of IL2 release-may trigger the activation of specific CTL. These could then recirculate and reach the potential sites of residual neoplastic disease. A cartoon illustrating the potential use of IL2 gene transfer technologies in the management of cancer patients is shown in Figure 1 . A further goal of this innovative approach-clearly not limited to the insertion of the IL2 gene-is that of eliciting an anti-tumour immunological memory within the T-lymphocytes of the host. The data so far accumulated support the above described theoretical considerations. The insertion of the IL2 cDNA has in fact been successfully accomplished in several murine tumours and this is coupled to the constitutive secretion of variable amounts of IL2 and to the generation of an antitumour response. Fearon et al. (1990) demonstrated that the injection in BALB/c mice of the weakly immunogenic CT26 murine colon cancer cells engineered to release IL2 was capable of generating an MHC class-I restricted CTL response against the parental tumour, mediated by CD8-positive cells. Furthermore, in the mice challenged with the IL2 transduced CT26 cells tumour growth could no longer be detected. The authors showed that the anti-tumour effect was due to CD8-positive CTLs and that it occurred also in the absence of CD4-positive T-cells, indicating that transduction of the IL2 gene could bypass T-cell helper requirement in the generation of an anti-tumour response. Finally, a protective immunity against further challenge by the parental, nontransduced cells could be documented. A similar evidence of inhibition of tumour growth, generation of a specific T-cell mediated cytotoxicity and durable anti-tumour memory has also been observed with the poorly immunogenic CMS5 fibrosarcoma cell line (Gansbacher et al., 1990b) . A reduction in the tumorigenic potential of a transplantable rat sarcoma infected with an IL2 cDNA has also been reported (Russell et al., 1991) ; furthermore, we have shown that in the murine B-lymphoma 38C13, following retroviral-mediated transfer of the IL2 gene, the transduced tumour cells showed a diminished in vivo growing capacity (Gansbacher et al., 1991 (Gastl et al., 1992; Gansbacher et al., 1992 Table II . It is, however, worth noting that a decreased or abolished tumorigenicity can be documented even with low levels of IL2 secreted. In order to obtain subclones of the bulk population capable of releasing higher quantities of IL2, the tumour cell lines can be cloned in semisolid medium or by limiting dilution. This procedure will, however, lead to the loss of the heterogeneous phenotipic representation of the primary tumour cell population which is likely to play an important role in the potential therapeutic exploitment of gene transfer technoligies.
Conclusions and perspectives
The results so far obtained in experimental models and, more recently, also with human neoplastic cells, suggest that transfer of cytokine/growth factor genes into neoplastic cells is no longer only a theoretical consideration, but rather it represents a reality which opens potential new prospects in released by the injected cells may elicit an anti-tumour immune response possibly contributed by the generation of cytotoxic cells specifically directed against the tumour, gains further strength by the recent evidence that in the peripheral blood of melanoma patients specific anti-tumour cytotoxic lymphocyte precursors have been described (Coulie et al., 1992) . It is conceivable that these cytotoxic cells may be amplified in vivo following repeated boosting with IL2-gene transduced tumour cells. The possibility that this may occur gains strength by the evidence that in the P815 mastocytomabearing mice the number of tumour-specific CTL could be increased following immunisation with IL2-producing tumour cells (Ley et al., 1991) . Hopefully, these cytotoxic effectors would then recirculate and reach the sites of residual disease, and, potentially, confer an anti-tumour immunological memory. Necessarily, the early clinical applications will have to be through phase I studies aimed at assessing the feasibility and safety of this new approach. It is, however, likely that this innovative therapeutic modality will find a more suitable and potentially fruitful use in the setting of patients with limited or minimal residual disease, where the tumour load is considerably lower and the immune system of the host less compromised. This latter aspect is further supported by studies in acute leukaemia, in which a marked defect of the killing machinery against autologous blasts has been documented at diagnosis and, to a further extent, at relapse, while in the remission phase of the disease there is often a restoration of the autologous killing capacity (Foa et al., 1991c) . In view of the potentially lowest tumour burden and of the presence of circulating cytotoxic effectors in patients who have undergone an autografting procedure (Reittie et al., 1989; Higuchi et al., 1989) , this clinical setting conceptually represents an optimal scenario for future protocols of gene-mediated vaccinations. Finally, since tumour specific antigens are being progressively recognised through more sophisticated cloning technologies (Van Der Bruggen et al., 1991; Chen et al., 1992) , it is realistic to speculate that in the near future more powerful and specific vectors containing both a given tumour antigen and the IL2 gene may be constructed and applied to the management of cancer patients. FROST, P. (1990 
